Targeting JNK to prevent antiretroviral neuropathy.
Laboratory of Neuropsychopharmacology, Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy.
Nicoletta
N
Galeotti
D000818:Animals; D044966:Anti-Retroviral Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D048670:MAP Kinase Kinase 4 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051379:Mice; D010523:Peripheral Nervous System Diseases / Q000209:etiology / Q000517:prevention & control*; D011788:Quality of Life; D011984:Sensory Receptor Cells / Q000473:pathology; D015398:Signal Transduction
D044966:Anti-Retroviral Agents; D004791:Enzyme Inhibitors; D048670:MAP Kinase Kinase 4
BDNF; JNK; NRTI; Neuroscience; antiretroviral; neuropathic pain